Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30345227 | 1.00 | TLR7 (0.58) | TLR7TLR8 | |
| SCHEMBL3863648 | 0.89 | TLR7 (0.57) | TLR7 | |
| SCHEMBL3863066 | 0.89 | TLR7 (0.60) | TLR7 | |
| SCHEMBL1950333 | 0.88 | TLR7 (0.62) | TLR7TLR8 | |
| SCHEMBL3865268 | 0.87 | TLR7 (0.66) | TLR7TLR8 | |
| SCHEMBL30346142 | 0.87 | TLR7 (0.58) | TLR7TLR8 | |
| SCHEMBL483348 | 0.87 | TLR7 (0.58) | TLR7TLR8 | |
| SCHEMBL5747604 | 0.87 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL20806194 | 0.87 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL22522221 | 0.87 | TLR7 (0.61) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155688-A1 | METHOD FOR GENERATING HUMAN DENDRITIC CELLS FOR IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-06-07 | — | — | US | claimed |
| EP-3298131-A1 | METHOD FOR GENERATING HUMAN DENDRITIC CELLS FOR IMMUNOTHERAPY | The Regents of The University of California (US) | 2018-03-28 | — | — | EP | claimed |
| WO-2016187459-A1 | METHOD FOR GENERATING HUMAN DENDRITIC CELLS FOR IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-24 | — | — | WO | claimed |
| US-6756382-B2 | SECONDARY AMIDES SUCH AS N-(4-(4-AMINO-2-(2-METHOXYETHYL)-1H-IMIDAZO(4,5-C)QUINOLIN-1-YL)BUTYL)-1 -METHYL-5-OXO-2-PYRIDIN-3-YLPYRROLIDINE-3-CARBOXAMIDE; BIOSYNTHESIS OF CYTOKINES; PROPYLAXIS OF VIRAL DISEASES; IMMUNOLOGY MODULATORS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-29 | — | — | US | claimed |
| US-20030144283-A1 | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-07-31 | — | — | US | claimed |
| US-20240033348-A1 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | Pulmotect, Inc. | 2024-02-01 | — | — | US | disclosed |
| US-20240002799-A1 | METHOD FOR GENERATING HUMAN DENDRITIC CELLS FOR IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-04 | — | — | US | disclosed |
| US-11826422-B2 | Methods and compositions for adaptive immune modulation | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-28 | — | — | US | disclosed |
| US-11680244-B2 | Method for generating human dendritic cells for immunotherapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-20 | — | — | US | disclosed |
| WO-2023070132-A1 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | OHIO STATE INNOVATION FOUNDATION (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-3298131-B1 | METHOD FOR GENERATING HUMAN DENDRITIC CELLS FOR IMMUNOTHERAPY | UNIV CALIFORNIA (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-3294295-B1 | TLR7 AND/OR TLR8 AGONISTS FOR THE TREATMENT OF BACTERIAL INFECTIONS IN PATIENTS SUFFERING FROM CIRRHOSIS | INST NAT SANTE RECH MED (FR) | 2021-08-04 | — | — | EP | disclosed |
| US-20090023722-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-22 | — | — | US | disclosed |
| US-20080193468-A1 | Method for Stimulating the Immune Response of Newborns | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2008-08-14 | — | — | US | disclosed |
| US-7393859-B2 | Amide substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393859-B2 | Amide substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393859-B2 | Amide substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-20040229897-A1 | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-11-18 | — | — | US | disclosed |
| US-6756382-B2 | SECONDARY AMIDES SUCH AS N-(4-(4-AMINO-2-(2-METHOXYETHYL)-1H-IMIDAZO(4,5-C)QUINOLIN-1-YL)BUTYL)-1 -METHYL-5-OXO-2-PYRIDIN-3-YLPYRROLIDINE-3-CARBOXAMIDE; BIOSYNTHESIS OF CYTOKINES; PROPYLAXIS OF VIRAL DISEASES; IMMUNOLOGY MODULATORS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-29 | — | — | US | disclosed |
| US-20030144283-A1 | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229897-A1 | Amide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 30/4885TLR8 72/4885 |
| US-20090023722-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | IFNG, IRF3, EIF2AK2 | TLR7 30/4885TLR8 72/4885 |
| US-20030144283-A1 | Amide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 30/4885TLR8 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.